Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

6 clinical studies listed.

Filters:

Cutaneous T-cell Lymphoma

Tundra lists 6 Cutaneous T-cell Lymphoma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT03380026

Mechlorethamine Induced Contact Dermatitis Avoidance Study

This is a two-arm, open-label study that aims to compare the incidence and severity of the most common adverse reactions, particularly contact dermatitis, when Valchlor is used alone or in conjunction with triamcinolone ointment 0.1% in early stage MF subjects (Stage IA and IB) for a period of 4 months.

Gender: All

Ages: 18 Years - Any

Updated: 2026-09-04

1 state

Cutaneous T-cell Lymphoma
Cutaneous T-cell Lymphoma Stage I
Mycosis Fungoides
+5
NOT YET RECRUITING

NCT07781449

Topical JAK-Inhibition of Early-Stage CTCL

This study tests whether a cream named delgocitinib (Anzupgo), applied twice daily to the skin, is safe and well tolerated in people with early-stage cutaneous T-cell lymphoma (a rare type of skin cancer called mycosis fungoides). The cream works by blocking proteins called JAK enzymes, which are involved in inflammation and cancer cell growth in the skin. Delgocitinib cream is already approved for treating chronic hand eczema, but it has not yet been studied in people with cutaneous T-cell lymphoma. In this study, up to 15 participants with stable, early-stage disease will apply the cream to their affected skin for 16 weeks. Researchers will closely monitor for side effects and also look at whether the cream improves skin symptoms, such as itching and the appearance of the skin. Participants will be followed for 4 additional weeks after treatment ends. This is an early, exploratory study (a "proof-of-concept" trial) designed mainly to check safety, not to prove that the treatment works. The findings will help researchers decide whether to test this cream in larger studies in the future.

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-26

Mycosis Fungoides
Cutaneous T-cell Lymphoma
NOT YET RECRUITING

NCT07714187

A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides

This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.

Gender: All

Ages: 18 Years - Any

Updated: 2026-07-20

1 state

Mycosis Fungoides
Cutaneous T-cell Lymphoma
RECRUITING

NCT05296304

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin. The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-04

1 state

Cutaneous T-cell Lymphoma
RECRUITING

NCT00177268

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.

Gender: All

Ages: 18 Years - Any

Updated: 2025-12-30

1 state

Cutaneous T-cell Lymphoma
Sezary Syndrome
Mycosis Fungoides
+2
RECRUITING

NCT04234048

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

Gender: All

Ages: 18 Years - Any

Updated: 2025-09-22

8 states

T-cell Lymphoma
Cutaneous/Peripheral T-Cell Lymphoma
Peripheral T-cell Lymphoma
+8